Evisceration and enucleation strongly linked to ocular injuries from IEDs

Article

Ocular injuries caused by improvised explosive devices (IEDs) are strongly associated with severe ocular damage repaired by evisceration or enucleation.

Ocular injuries caused by improvised explosive devices (IEDs) are strongly associated with severe ocular damage repaired by evisceration or enucleation, states an investigation published in Eye.

Dr F.C. Erdurman et al., Department of Ophthalmology, Gulhane Military Medical Academy and School of Medicine, Ankara, Turkey, conducted a retrospective review of 61 eyes of 39 patients who had suffered from ocular injuries caused by IEDs. The average patient age was 24 years and the average follow-up was 6 months. Of the patients studied, 49 eyes had open-globe injuries and 12 eyes had closed-globe injuries.

The results showed that eyes with open-globe injury experienced a higher rate of intraocular foreign body (IOFB) injury with 76% of eyes presenting with it. Evisceration or enucleation as a primary surgical intervention was needed in 28% of eyes and 36% of eyes presented with no light perception.

At the final follow-up 43% of eyes demonstrated no light perception. In eyes that underwent vitreoretinal surgery 50% of them developed postoperative proliferative vitreoretinopathy (PVR). Postoperative PVR was identified as the most frequent cause of poor visual outcome.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.